Fixation for implantable medical devices

Information

  • Patent Grant
  • 10518084
  • Patent Number
    10,518,084
  • Date Filed
    Tuesday, September 11, 2018
    5 years ago
  • Date Issued
    Tuesday, December 31, 2019
    4 years ago
Abstract
A tine portion of an implantable medical device includes a hook segment and a distal segment terminated by a tissue-piercing tip, wherein the distal segment extends from a distal end of the hook segment to the tip. The hook segment, which is elastically deformable from a pre-set curvature, for example, defined by a single radius, preferably tapers from a first width thereof, in proximity to a proximal end thereof, to a smaller, second width thereof, in proximity to the distal end thereof, wherein the tip has a width that is greater than the second width of the hook segment. Alternately, the tine portion may include a hook segment that is defined by two radii and a straight section extending therebetween.
Description
TECHNICAL FIELD

The present invention pertains to implantable medical devices, and, more specifically, to tissue-penetrating fixation components thereof.


BACKGROUND

An implantable medical device, for the delivery of stimulation therapy and/or for diagnostic sensing, may include at least one tissue-penetrating fixation component configured to hold the device at an implant location. FIG. 1 is a schematic diagram that shows potential cardiac implant sites for such a device, for example, within an appendage 102 of a right atrium RA, within a coronary vein CV (via a coronary sinus ostium CSOS), or in proximity to an apex 103 of a right ventricle RV. FIG. 2 is a plan view of an exemplary implantable medical device 200, which includes a tissue-penetrating fixation component formed by a plurality of tine portions 230. FIG. 2 further illustrates device 200 including a hermitically sealed housing 220 that contains control electronics and a power source (not shown), and which defines a longitudinal axis 2 of device 200. Housing 220 may be formed from a medical grade stainless steel or titanium alloy and have an insulative layer formed thereover, for example, parylene, polyimide, or urethane. With further reference to FIG. 2, device 200 includes a pair of electrodes 261, 262, which may form a bipolar pair for cardiac pacing and sensing; tine portions 230 surround electrode 261 and are configured to penetrate tissue in order to hold electrode 261 in intimate contact with tissue, for example, at one of the aforementioned implant sites, while securing, or fixating device 200 for chronic implantation at the site. Further description of a suitable construction for device 200 may be found in the co-pending and commonly assigned United States patent application having the pre-grant publication number 2012/0172690 A1.


With reference to FIG. 3A, device 200 may be delivered to an implant location via a delivery catheter 300. For example, with reference to FIG. 1, if the target implant site is located in the right atrium RA, coronary vein CV, or right ventricle RV, a distal end 310 of catheter 300 may be maneuvered into the heart through a superior vena cava SVC or an inferior vena cava IVC, according to a transvenous delivery method known in the art. FIG. 3A shows a partial cross-section of distal end 310 of catheter 300, which is formed like a cup to hold and contain device 200 for delivery to the implant site. FIG. 3A illustrates device 200 having been loaded into distal end 310 so that a hook segment 231 of each tine portion 230 is elastically deformed, from a pre-set curvature thereof, to an open position, at which a distal segment 232 of each tine portion 230 extends distally toward an opening 313 of catheter distal end 310. Each tine portion 230 is preferably formed from a superelastic material, such as Nitinol. FIG. 3A further illustrates a deployment element 320 abutting a proximal end of device 200 and extending proximally therefrom, through a lumen of catheter 300, and out from a proximal opening 301 thereof. Element 320 may be moved, per arrow M, by an operator to push device 200, per arrow P, out from opening 313 of distal end 310, for example, when opening 313 has been located by the operator in close proximity to tissue at the target implant site.



FIG. 3B, is an enlarged view of distal segment 232 of one of tine portions 230, wherein a tissue-piercing tip 322, which terminates distal segment 232, has just been pushed out through opening 313 of distal end 310 of catheter 300 and into contact with tissue T. FIG. 3B illustrates distal segment 232 supported by the surrounding wall of distal end 310, in proximity to opening 313, so that the push force of deployment element 320 is effectively transferred through tip 322 to first compress the tissue T, as shown, and then to pierce the tissue T for penetration therein, which is shown in FIGS. 3C-D. FIGS. 3C-D illustrate partial tine penetration and full tine penetration, respectively, as deployment element 320 continues to push device 200 out opening 313. It can be seen that the elastic nature of each tine portion 230, once the constraint of the distal end 310 is withdrawn, allows the corresponding hook segment 231 to relax back toward the pre-set curvature thereof within the tissue. The full penetration of tine portions 230, shown FIG. 3D, is representative of acute fixation of device 200 at the implant site, for example, for the evaluation of device performance (e.g., pacing and sensing via electrodes 261, 262). It should be noted that, at some implant sites, tine portions 230 may, at full penetration, extend back out from tissue T, for example, generally toward distal end 310 of catheter 300.


With further reference to FIG. 3D, a tether 350 is shown looping through an eye feature 205 formed at the proximal end of device 200; tether 350 extends proximally through a lumen of deployment element 320 to a proximal end 351 thereof, outside a proximal end of deployment element 320, which may be seen in FIG. 3A. Thus, if the performance of acutely fixated device 200 is unsatisfactory, the operator may use tether 350 to pull device 200 back into distal end 310, thereby withdrawing tine portions 230 from the tissue, so that device may be moved by delivery catheter 300 to another potential implant site. Alternately, if the acutely fixated device 200 performs satisfactorily, proximal end 351 of tether 350 may be severed to pull tether 350 out from eye feature 205 of device 200, and the fully penetrated tine portions 230 continue to fixate device 200 for chronic implant.


The aforementioned co-pending and commonly assigned U.S. patent application '690 discloses suitable embodiments of a fixation component having tine portions similar to tine portions 230, wherein the tine portions exhibit a suitable baseline performance, for example, in terms of a deployment force, an acute retraction force (for repositioning), atraumatic retraction, and acute and chronic fixation forces. Yet, there is still a need for new configurations of tine portions for implantable devices, like device 200, that may further enhance fixation.


SUMMARY

Some embodiments of the present invention encompass implantable medical devices (e.g., cardiac pacemakers) and tissue-penetrating fixation components thereof, which include one or more tine portions configured for increased strain relief during the flexing thereof, either at initial implant (particularly in cases where the retraction of penetrated tines is necessary for repositioning the device), or when subject to cyclic loading during a chronic implant of the fixated device, for example, within a beating heart. These tine portions are, preferably, also configured to reduce the risk of tissue trauma during the retraction thereof from the tissue, for example, for repositioning. In certain embodiments, a tissue-penetrating fixation component for an implantable medical device includes a tine portion configured to mitigate the risk of compressing, for example, to the point of occlusion, blood vessels in proximity to the implant site, without sacrificing chronic fixation performance, and while maintaining adequate strain relief.


According to some embodiments, a tine portion of a tissue-penetrating component of an implantable medical device includes a hook segment and a distal segment terminated by a tissue-piercing tip. The hook segment, which is pre-set to extend along a curvature that encloses an angle of between 135 degrees and 270 degrees, from a proximal end thereof, in proximity to the base portion, to a distal end thereof, and which is elastically deformable from the pre-set curvature to an open position, tapers from a first width thereof, in proximity to the proximal end thereof, to a second width thereof, in proximity to the distal end thereof, the second width being less than the first width. The distal segment, which is pre-set to extend along a relatively straight line, approximately tangent to the distal end of the hook segment, from the distal end of the hook segment, is terminated by a tissue-piercing tip that, preferably, has a width that is greater than the second width of the hook segment. The first width of the hook segment may be approximately two to five times greater than the second width thereof, and the width of the tissue-piercing tip may be two to three times greater than the second width.


According to some embodiments, in which a length of the distal segment of the tine portion is relatively short, to mitigate the risk of vessel compression, the distal segment either extends approximately parallel to a longitudinal axis of the component/device, or away from the longitudinal axis, when the hook segment conforms to the pre-set curvature.


According to some embodiments, in which the tissue-penetrating component further includes a base portion, for example, in the form of a ring, that defines the aforementioned longitudinal axis and is configured to be fixedly attached to the implantable medical device, the tine portion further includes a proximal segment that extends between the hook segment and the base portion, wherein the proximal segment may extend from the base portion toward the longitudinal axis.





BRIEF DESCRIPTION OF THE DRAWINGS

The following drawings are illustrative of particular embodiments of the present invention and therefore do not limit the scope of the invention. The drawings are not to scale (unless so stated) and are intended for use in conjunction with the explanations in the following detailed description. Embodiments will hereinafter be described in conjunction with the appended drawings wherein like numerals/letters denote like elements, and:



FIG. 1 is a schematic diagram showing potential implant sites for embodiments of the present invention;



FIG. 2 is a plan view of an exemplary implantable medical device;



FIG. 3A is a plan view of the medical device loaded in a delivery catheter, according to some embodiments, wherein tine portions of a tissue-penetrating fixation component thereof are elastically deformed into an open position;



FIG. 3B is an enlarged detail view of one of the tine portions initially contacting tissue at an implant site;



FIGS. 3C-D are plan views of the device and catheter in subsequent steps of implanting the device, when the tine portions have penetrated the tissue;



FIG. 4A is a schematic representation of a flexing tine portion;



FIG. 4B is a perspective view of a tapered tine portion, according to some embodiments of the present invention;



FIG. 5 is an estimated penetration path and an ‘as set’ relaxation plot for a tine portion of the exemplary device shown in FIG. 2;



FIG. 6A is a plan view of an implantable medical device, according to some embodiments of the present invention;



FIG. 6B is a perspective view of a tissue-penetrating fixation component, according to some embodiments of the present invention, separated from the device of FIG. 6A;



FIG. 6C is an elevation view of the component of FIG. 7B, according to some embodiments;



FIG. 6D is a plan view of a tine portion of the component of FIG. 7B, according to some embodiments;



FIG. 7A is an elevation view of a tissue-penetrating fixation component, according to some alternate embodiments, which may be incorporated in the device of FIG. 6A;



FIG. 7B is an estimated penetration path and an ‘as set’ relaxation plot for a tine portion of the component shown in FIG. 7A;



FIGS. 8A-B are plan views of tine portions, according to some alternate embodiments;



FIGS. 9A-D are profiles and corresponding estimated penetration path and ‘as set’ relaxation plots of various tine portions, according to additional embodiments;



FIG. 10A is a plan view of an implantable medical device, according to some alternate embodiments of the present invention;



FIG. 10B is a perspective view of a tissue-penetrating fixation component, according to some embodiments, separated from the device of FIG. 10A;



FIG. 10C is an enlarged detail view of a distal segment of one of the tine portions of the FIG. 10B component initially contacting tissue at an implant site;



FIG. 11A is an elevation view of a tissue-penetrating fixation component, according to yet further embodiments of the present invention, which may be incorporated in the exemplary device of FIG. 10A; and



FIG. 11B is a plan view of a tine portion of the component of FIG. 11A, according to some embodiments.





DETAILED DESCRIPTION

The following detailed description is exemplary in nature and is not intended to limit the scope, applicability, or configuration of the invention in any way. Rather, the following description provides practical examples, and those skilled in the art will recognize that some of the examples may have suitable alternatives.



FIG. 4A is a schematic representation of one of tine portions 230 isolated from the above-described implantable medical device 200, wherein an exemplary flexing, per arrow F, of tine portion 230 is illustrated. Such flexing may be encountered by tine portion 230, once tine portion 230 has penetrated tissue to fix device 200 at a chronic implant site for cardiac monitoring and/or therapy, for example, as illustrated in FIG. 3D. Thus, fatigue life is a consideration influencing the configuration of tine portions for those implantable medical devices that may be subjected to cyclic loading caused by hundreds of millions of heart beats, over the life of their implant. In FIG. 4A, a zone of stress concentration SC, for example, in response to the flexing per arrow F, is circled; zone SC is located in proximity to a proximal end 31 of hook segment 231 of tine portion 230, where hook segment 231 joins with a base portion 203. Base portion 203 and tine portion 230 may be integrally formed, wherein base portion 203 is configured to be fixedly attached to device 200. Stress concentration in zone SC may also result from deformation of hook segment 231 into the open position (FIG. 3A), for example, upon initial loading of device 200 and retraction of device 200 back into distal end 310 of catheter for repositioning, which, in combination with the repeated force of deployment, can potentially push tine portion 230 toward an elastic limit and may make tine portion 230 subsequently more vulnerable to fatigue under the aforementioned cyclic loading. Although rounded edges of tine portions 230 effectively reduce the concentration of stress, as previously described in the aforementioned commonly-assigned U.S. patent application '690, some embodiments of the present invention incorporate tine portions that have tapered hook segments to further address the stress concentration, for example, as illustrated in FIG. 4B.



FIG. 4B is a perspective view of a tine portion 430, according to some embodiments, one or more of which may be integrated into device 200, as substitute for tine portions 230. A base portion 403 is shown integrally formed with tine portion 430, according to some preferred embodiments, wherein base portion 403 is configured for attachment to a medical device, such as device 200. FIG. 4B illustrates a hook segment 431 of tine portion 430 extending from a first end 41 thereof, in proximity to base portion 403, to a second end 42 thereof, in proximity to a distal segment 432 of tine portion 430, wherein hook segment 431 tapers from a first width W1, in proximity to proximal end 41, to a smaller, second width W2, in proximity to a distal end 42 of hook segment 431. The tapering of hook segment 431 provides strain relief during the aforementioned deformation/flexing, to alleviate the aforementioned stress concentration. FIG. 4B further illustrates an optional slot 48 (dashed lines), which may be formed through a thickness t of tine portion 430, and extend between first width W1 and second width W2. The inclusion of slot 48 provides an additional means for providing strain relief, for example, when a limit on how narrow second width W2 may be, for example, no smaller than approximately 0.020-0.025 inch, so that distal segment 432 does not tear tissue upon retraction therefrom. According to some embodiments, optional slot 48 may include internal shear tabs (not shown) to help distribute out of plane loads, for example, orthogonal to the illustrated direction of flexing, per arrow F of FIG. 4A.


With further reference to FIGS. 4A-B, distal segment 432 of tine portion 430 is shown having a shorter length than distal segment 232 of tine portion 230, for example, to provide more flexibility in selecting a suitable implant site without risking undue trauma to tissue, upon penetration of tine portion 430 at the selected site. The shorter length can help to prevent perforation through the wall of a structure, for example, the heart, at some implant locations, and can reduce a probability for penetrated tine portions 430 to interfere with blood vessels, which interference, for example, may compromise coronary blood supply, as will be described below in conjunction with FIG. 5.



FIG. 5 is an estimated tissue penetration path and an ‘as set’ relaxation plot for tine portion 230 of device 200 (FIG. 2), wherein tine portion 230 is formed from approximately 0.005 inch thick Nitinol. FIG. 5 includes a solid line, which represents the profile of tine portion 230 when device 200 is loaded in distal end 310 of catheter 300 (FIG. 3A) with hook segment 231 deformed to the open position. With reference back to FIGS. 3A-D, the origin, or zero coordinate, along the ordinate axis generally corresponds to the constraining wall of distal segment 310 of delivery catheter 300. The plot of FIG. 5 is made up of a segmented line connecting circles, which corresponds to the estimated penetration path of tine portion 230, for example, when device 200 is pushed out from distal end 310 and into tissue T (FIGS. 3B-D), and a dashed line, which represents the profile of tine portion 230, according to the pre-set curvature, toward which the penetrated tine portion 230 relaxes over time. The volume of tissue between the segmented line and the dashed line approaches that which is squeezed or compressed by the penetrated tine portion 230 as it relaxes over time; the greater this volume, the greater the probability for the penetrated tine to compress or pinch one or more blood vessels that perfuse the tissue. For example, the dotted line in FIG. 5 represents a potential coronary artery that may be compressed or pinched by tine portion 230. As alluded to above, the length of distal segment 232 is a factor contributing to the volume that is squeezed by penetrated tine portion 230, so that reducing the length of distal segment 232 may be desired. However, if the length of distal segment 232 is reduced, without modifying other aspects of tine portion 230, an orientation of tine portion 230 relative to tissue T, when hook segment 231 is in the open position, will be impacted such that tine portion 230 may be less likely to effectively penetrate into tissue T, for example, upon exiting through opening 313 of distal end 310 of catheter 300 (FIGS. 3A-B). Therefore, with reference to FIG. 4B, the tapering of hook segment 431 of tine portion 430 not only relieves strain but also allows for a more favorable orientation of the shorter distal segment 432 for tissue penetration (e.g., being directed along a line that is closer to normal to the tissue surface), when hook segment 431 is in the open position.


Various embodiments of tine portions for fixation of an implantable medical device, for example, as described below, incorporate a tapered hook segment and/or a shorter distal segment, to address the above described cyclic loading and/or potential tissue trauma. The following embodiments have been configured with reference to prior art tine portions of tissue-penetrating fixation components for medical devices, such as those described in the aforementioned commonly assigned U.S. patent application '690 (generally corresponding to tine portion 230), in order to allow a similar fit of devices, like device 200, within a delivery catheter, for example, having the tine portions deformed into the open position within distal portion 310 of catheter 300, and to maintain suitable baseline performance, for example, in terms of a deployment force (e.g., no greater than approximately 1-2 Newtons for a fixation component having four tine portions), an acute retraction force, for repositioning (e.g., between approximately 3-4 Newtons for a fixation component having four tine portions), atraumatic retraction, and an adequate acute fixation force (e.g., greater than approximately 2.5 Newtons for a fixation component having four tine portions).



FIG. 6A is a plan view of a medical device 600, according to some embodiments of the present invention. FIG. 6A illustrates device 600 including a hermitically sealed housing 620 and a pair of electrodes 661, 662; housing 620, like housing 220 of device 200, contains control electronics and a power source (not shown), which, for example, together with electrodes 661, 662, are adapted for cardiac pacing and sensing. FIG. 6A further illustrates device 600 including tine portions 630, which are adapted to penetrate tissue in order to secure device 600 at an implant site, for example, a cardiac site in the right atrium RA or the right ventricle RV (FIG. 1), having been deployed from distal end 310 of delivery catheter 300 (FIGS. 3A-D). According to some embodiments, tine portions 630 are included in a tissue-penetrating fixation component 63, which is shown, separate from device 600, in FIG. 6B.



FIG. 6B illustrates component 63 also including a base portion 603, from which tine portions 630 extend, preferably being integrally formed therewith, as described below. According to the illustrated embodiment, base portion 603 of fixation component 63 defines a longitudinal axis 6 of component 63 and is configured for attachment to device 600 so that axis 6 is approximately aligned with a longitudinal axis 20 of device 600. Component 63 may be part of a subassembly that forms a distal end of device 600, and which also includes electrode 661; such a subassembly is described in the aforementioned commonly-assigned U.S. patent application '690, in conjunction with FIGS. 3A-4B thereof, the description of which is hereby incorporated by reference. FIG. 6B further illustrates each tine portion 630 of tissue-penetrating component 63 including a hook segment 631 and a distal segment 632.


With reference to FIG. 6C, which is an elevation view of component 63, each hook segment 631 extends along a pre-set curvature that encloses an angle θ, from a proximal end 61 thereof to a distal end 62 thereof. FIG. 6C illustrates each distal segment 632 extending along a relatively straight line that is approximately tangent to distal end 62 of hook segment 631. According to the illustrated embodiment, angle θ is less than 180 degrees, such that distal segment 632 extends away from axis 6. FIG. 6C further illustrates the preset curvature of hook segment 631 being defined by a single radius R. According to an exemplary embodiment, radius R is approximately 0.085 inch, an angle β, at which distal segment extends relative to axis 6, is approximately 20 degrees, and a length LD of distal segment 632 is between approximately 0.05 inch and approximately 0.1 inch.


According to some preferred embodiments, component 63 is manufactured by, first, laser cutting base portion 603 and tine portions 630, together, from a tube of superelastic and biocompatible metal (e.g., Nitinol), and then wrapping and holding each tine portion 630 about a mandrel for a heat setting process that pre-sets the illustrated curvature of each hook segment 631. Manufacturing methods such as these are known to those skilled in the art of forming Nitinol components. Although FIG. 6B shows base portion 603 of component 63 formed as a ring, wherein tine portions 630 are integrally formed therewith and spaced apart from one another about a perimeter of the ring, in alternate embodiments of tissue penetrating fixation components, one or more tine portions may be formed individually and then attached to a base portion that is configured in any suitable fashion for attachment to device 600.



FIG. 6D is a plan view of one of tine portions 630, prior to forming the pre-set curvature thereof, in which the above-described tapering for strain relief along hook segment 631, from first width W1 to smaller, second width W2 may be seen. When, for example, in the aforementioned exemplary embodiment, component 63 is manufactured from Nitinol tubing that has a thickness of approximately 0.005 inch, and hook segment 631 thereof has a length LH of approximately 0.23 inch, first width W1 may be between approximately two to five times greater than second width W2 to provide strain relief for improved fatigue life. Yet, if the smaller, second width W2, for example, being approximately 0.010 inch, were to define an entirety of distal segment 632, distal segment 632 may tear tissue upon retraction therefrom, for example, when repositioning device 600. So, with further reference to FIG. 6D, distal segment 632 of tine portion 630 is terminated by a tissue-piercing tip 622 that has a width W3, which is greater than second width W2, for example, approximately two to three times greater, in order to be atraumatic to tissue. In the aforementioned exemplary embodiment, first width W1 is between approximately 0.034 inch and approximately 0.05 inch, second width W2 is approximately 0.010 inch, and third width W3 is approximately 0.02 inch.



FIG. 7A is an elevation view of a tissue-penetrating fixation component 73, according to some alternate embodiments of the present invention, which may be incorporated in device 600 as an alternative to component 63, such that a longitudinal axis 7 of component 73 is approximately aligned with longitudinal axis 20 of device 600. FIG. 7A illustrates component 73 including a base portion 703, similar to base portion 603 of component 63, and a plurality of tine portions 730, each of which includes a hook segment 731 and a distal segment 732. Tine portions 730 and base portion 703 are preferably integrally formed according to the method described above for component 63. Furthermore, each tine portion 730, prior to the pre-setting of a curvature of hook segment 731, may be configured like tine portion 630 as described above in conjunction with FIG. 6D, wherein the aforementioned exemplary values for widths W1, W2, W3, thickness t and lengths LD, LH are suitable. However, with further reference to FIG. 7A, the pre-set curvature along which hook segment 731 extends, from a first end 71 thereof and a second end 72 thereof, encloses an angle φ, which is 180 degrees, so that distal segment 732 extends, between a tissue-piercing tip 722 thereof and second end 72 of hook segment 731, along a line that is approximately parallel to axis 7. The pre-set curvature of hook segment 731, like hook segment 631, is defined by a single radius R, which may be approximately 0.085 inch.



FIG. 7B is an estimated penetration path and an ‘as set’ relaxation plot for tine portion 730 of component 73, which may be compared to that of tine portion 230 (FIG. 5). FIG. 7B illustrates, with a solid line, tine portion 730 having been elastically deformed into the open position, for example, as would be the case when device 600 includes component 73 and is loaded within a delivery catheter, for example, distal end 310 of delivery catheter 300 (FIG. 3A). In comparing the solid lines of FIGS. 5 and 7B, it may be appreciated how the strain relief of tapering flattens the deformed profile of tine portion 730 relative to that of tine portion 230, and that the open position of tine portion 730 orients distal segment 732 of tine portion 730 along a line that is nearly normal to the ordinate axis, which generally corresponds to the above-described tissue surface, for effective tissue penetration. Furthermore, in comparing the estimated tissue penetration path of tine portions 230 and 730 (segmented lines connecting the circles), relative to the corresponding relaxed profiles (dashed lines), it can be seen that, due to the shorter length and more open pre-set curvature, tine portion 730 does not encompass as large a volume of tissue, relative to the pre-set curvature, toward which the penetrated tine portion 730 relaxes over time, upon full penetration, so that the above described risk of perforation and/or pinching of blood vessels is reduced.



FIGS. 8A-B are plan views of tine portions 830A, 830B, prior to pre-setting a curvature thereof, according to some alternate embodiments, either of which may be formed in component 63, 73 in lieu of tine portions 630, 730, for example, to increase the ease of tolerance control and inspection. FIGS. 8A-B illustrate hook segments 831A, 831B of tine portions 830A, 830B having a single-sided, or asymmetric taper. According to the illustrated embodiments, widths W1, W2, and W3 are designated at generally the same locations along hook segments 831A, 831B and distal segments 832A, 832B, as previously described for tine portions 630 and 730. Furthermore, it should be understood that, according to some preferred embodiments, a thickness of each tine portion 830A, 830B (into the page), for example, approximately 0.005 inch, is approximately constant along an entire length of each tine portion 830A, 830B, since components that would include tine portions 830A, 830B are preferably formed from a Nitinol tube according to the method described above. FIG. 8A further illustrates distal segment 832A of tine portion 830A being terminated in a tissue-piercing tip 822, at which width W3 has a center line that is offset from a center line of second width W2; while FIG. 8B illustrates a tissue-piercing tip 822B of distal segment 832B, at which width W3 has a center line approximately aligned with that of second width W2. According to some exemplary embodiments, first width W1 is between approximately 0.034 inch and approximately 0.05 inch, second width W2 is approximately 0.010 inch, and third width W3 is approximately 0.02 inch.



FIGS. 9A-D are profiles and corresponding estimated penetration path and ‘as set’ relaxation plots of various tine portions 930A, 930B, 930C, 930D, according to yet further embodiments of the present invention, wherein the profiles, per the pre-set curvatures of hook segments 931A-D, accommodate for a relatively shorter length of distal segments 932A-D thereof, for example, compared to that of tine portion 230 (FIG. 5). FIGS. 9A-D illustrate the pre-set curvature of each hook segment 931A-D being defined by two radii, R1 and R2, wherein R2 is greater than R1. According to exemplary embodiments of tine portions 930A, 930B, radius R1 is approximately 1.04 mm and radius R2 is approximately 1.65 mm, while in an exemplary embodiment of tine portion 930C, radius R1 is approximately 0.5 mm and radius R2 is approximately 1.65 mm, and, in an exemplary embodiment of tine portion 930D, radius R1 is 0.25 mm and radius R2 is approximately 2.4 mm. It should be noted that none of tine portions 930A-D, as depicted in the corresponding plots, include tapering along the corresponding hook segments 931A-D thereof. Yet, it is contemplated that a tapering of hook segments 931A-D, for example, similar to that described above, will provide strain relief for improved fatigue life and allow for shorter tine portions 930A-D without compromising the orientation of distal segments 932A-D, when hook segments 931A-D are deformed into the open position.


Each of tine portions 930A-D may be one of a plurality, which are included in a tissue-penetrating component, and that extend from a base portion 903 of the component, wherein base portion 903 defines an axis 9 of the component, and may be similar to the above described base portions 603, 703 of components 63, 73. FIGS. 9A-D further illustrate each of tine portions 930A-D including a proximal segment 933A-D that extends between base portion 903 and the corresponding hook portion 931A-D. Each of proximal segments 933A, 933B is shown extending approximately parallel to axis 9, while each of proximal segments 933C, 933D is shown extending from base portion 903 toward axis 9, for example, to increase an overall arc length of each of tine portions 930C, 930D for added flexibility during retraction into catheter distal end 310 (FIGS. 3A-C), when the corresponding hook segment 931C, 931D is being elastically deformed to the open position (solid line of plots). Furthermore, although the orientation of distal segments 932C, 932D, when tine portions 930C, 930D are in the open position, is less favorable for ease of tissue penetration that that of other embodiments, the extension of proximal segments 933C, 933D toward axis 9 can contribute to a reduction in compressed tissue volume without a tapering of hook segments 931C, 931D.


With further reference to FIGS. 9B-C, each hook portion 931B, 931C is also defined by a straight section S that extends between radii R1, R2. With further reference to the solid lines in the plots of FIGS. 9A-D, it may be seen how straight sections S can somewhat flatten the opened profile of tine portions 930B, 930C. Finally, in comparing the segmented lines of the FIG. 9A-D plots, which correspond to the estimated tissue penetration path of each of tine portions 930A-D, to that in the FIG. 5 plot for tine portion 230, it can be appreciated that the relatively shorter lengths of distal segments 932A-D, in combination with the corresponding profiles of tine portions 930A-D, lead to a reduction in tissue volume that is potentially compressed by each of the penetrated tine portions 930A-D during subsequent relaxation toward the pre-set curvature (dashed lines).


Because a reduction in the length, and/or tapering for strain relief of tine portions, can, in some instances, hinder initial tine penetration upon deployment (e.g., according to the method described above in conjunction with FIGS. 3B-C), additional embodiments of the present invention, which are described below in conjunction with FIGS. 10A-C and FIGS. 11A-B, include tissue-piercing distal tips that are configured to enhance initial tine penetration. With reference to FIGS. 3A-B, the initial penetration of tine portions 230 rely upon a stiffness of tine portions 230 being greater than that of tissue T, and upon an orientation of tissue-piercing tip 322 relative to tissue T, when device 200 is loaded in catheter distal end 310, with hook segments 31 elastically deformed into the open position.



FIG. 10A is a plan view of an implantable medical device 500, according to some embodiments of the present invention. FIG. 10A illustrates device 500 including a hermitically sealed housing 520 and a pair of electrodes 561, 562; housing 520, like housing 220 of device 200, contains control electronics and a power source (not shown), which, for example, together with electrodes 561, 562, are adapted for cardiac pacing and sensing. FIG. 10A further illustrates device 500 including tine portions 530, which are adapted to penetrate tissue in order to secure device 500 at an implant site, for example, a cardiac site in the right atrium RA or the right ventricle RV (FIG. 1).



FIG. 10B is a perspective view of a tissue-penetrating fixation component 53, according to some embodiments of the present invention, which is shown separated from device 500, and which includes tine portions 530. FIG. 10B illustrates component 53 also including a base portion 503, from which tine portions 530 extend. According to the illustrated embodiment, base portion 503 of fixation component 53 defines a longitudinal axis 5 of component 53 and is configured for attachment to device 500 so that axis 5 is approximately aligned with a longitudinal axis 25 of device 500. Component 53 may be part of a subassembly that forms a distal end of device 500, and which also includes electrode 561, for example, like the aforementioned subassembly that is disclosed in the above referenced and incorporated by reference passages of the detailed description of commonly-assigned U.S. patent application '690.



FIG. 10B further illustrates each tine portion 530 of tissue-penetrating fixation component 53 including a hook segment 531 and a distal segment 532. Each hook segment 531 is shown extending along a curvature that encloses an angle ψ, from a proximal end 51 thereof to a distal end 52 thereof; and each distal segment 532 is shown extending along a relatively straight line that is approximately tangent to distal end 52 of hook segment 531. Each distal segment 532 is shown extending toward axis 5, and, according to an exemplary embodiment, angle ψ is approximately 200 degrees. According to some preferred embodiments, component 53 is manufactured by, first, laser cutting base portion 503 and tine portions 530, together, from a tube of superelastic and biocompatible metal (e.g., Nitinol), and then wrapping and holding each tine portion 530 about a mandrel for a heat setting process that pre-sets the illustrated curvature of each hook segment 531. As mentioned above, manufacturing methods such as these are known to those skilled in the art of forming Nitinol components. Although FIG. 10B shows base portion 503 of component 53 formed as a ring, wherein tine portions 530 are integrally formed therewith, and spaced apart from one another about a perimeter of the ring, in alternate embodiments of tissue penetrating fixation components, one or more tine portions may be formed individually and then attached to a base portion that is configured in any suitable fashion for attachment to device 500.


In order to provide more flexibility in selecting a suitable implant location for device 500, a length of distal segment 632 of each tine portion 630 is relatively short compared to that of distal segment 232 of tine portion 230, for example, between approximately 0.05 inch and approximately 0.1 inch. The shorter length can help to prevent perforation through the wall of a structure, for example, the heart, at some implant locations, and can reduce a probability for penetrated tine portions 530 to interfere with blood vessels, which interference, for example, may compromise coronary blood supply, as described above. However, with reference back to FIGS. 3A-C, after device 500 is loaded in distal end 310 of catheter 300, and opening 313 of distal end 310 is positioned in proximity to tissue at a potential implant site, the reduced length of tine portions 530 may hinder initial tine penetration. A sharper terminal end of distal segment 532 can solve this problem but may lead to tissue tearing, upon insertion and/or retraction; thus a relatively blunt terminal end of distal segment 532 is preferred. So, with further reference to FIG. 10B, each distal segment 532 includes a tooth 520 and a relatively blunt end 540, which surrounds tooth 520.



FIG. 10B illustrates end 540 including a pair of legs 541 and a distal arch 542 that extends between legs 541, distal to tip 522 of tooth 520, for example, being spaced apart therefrom by approximately 0.005 inch. Each tooth 520 has a length, which is defined from a foot 521 thereof to a tissue-piercing tip 522 thereof, for example, being between approximately 0.025 inch and approximately 0.045 inch, and legs 541 extend along the length of tooth 520, on opposing sides thereof. Each tooth 520 and corresponding end 540 may be laser cut at the same time that tine portions 530 and base portion 503 are cut from the aforementioned tube.


According to the illustrated embodiment, legs 541 of end 540 are configured to bend in elastic deformation when distal arch 542 is pushed against tissue at a potential implant site, for example, as illustrated in FIG. 10C, so that tip 522 of tooth 520, which is configured to resist bending, is exposed to pierce the tissue. FIG. 10C is an enlarged detail view of distal segment 532 as tine portion 530 is pushed into contact with tissue T at the implant site. With reference back to FIGS. 3A-B, it should be understood that pushing distal arch 542 against the tissue T may be accomplished, as described above for device 200, after device 500 is loaded into distal end 310 of catheter 300 so that hook segments 531 of tine portions 530 are elastically deformed into the open position, at which distal segments 532 are directed distally toward opening 313 of distal end 310. After tip 522 of each tooth 520 has pierced the tissue, in response to the relatively high push force for initial deployment, legs 541 of end 540 can relax back into line with tooth 520 so that distal arch 542, upon subsequent penetration/insertion of tine portions 530 into tissue, and upon retraction thereof from the tissue, if necessary, prevents tip 522 from tearing the tissue. With reference back to FIG. 10B, according to an exemplary embodiment, a thickness t of each tine portion 530, which is relatively constant along the entire length thereof, is approximately 0.005 inch, a width wf of foot 521 of tooth 520 is between approximately 0.010 inch and approximately 0.015 inch, a width wt of tip 522 of tooth 520 is approximately 0.003 inch, and a width we of legs 541 and distal arch 542 is approximately 0.005 inch.



FIG. 11A is an elevation view of a tissue-penetrating fixation component 83, according to some alternate embodiments of the present invention, which may also be incorporated in the exemplary device of FIG. 10A. FIG. 11A illustrates component 83 including a base portion 803 and a plurality of tine portions 830 extending therefrom, similar to component 53, wherein each tine portion 830 includes a hook segment 831 and a distal segment 832 that are configured to address both of the aforementioned issues related to tissue penetration and fatigue life. Component 83 may be cut and formed from a Nitinol tube in a manner similar to that described above for component 53. FIG. 10A further illustrates each hook segment 831 being pre-set to extend along a curvature that encloses angle φ, from a proximal end 81 thereof to a distal end 82 thereof; and each distal segment 832 is shown extending along a relatively straight line that is approximately tangent to distal end 82 of hook segment 831. According to the illustrated embodiment, angle γ is approximately 180 degrees, so that each distal segment 832 extends approximately parallel to a longitudinal axis 8 of component 83. The pre-set curvature of hook segment 831 is defined by a single radius R, which may be approximately 0.085 inch.



FIG. 11B is a plan view of tine portion 830, prior to forming the pre-set curvature thereof. FIGS. 11A-B illustrate each tine portion 830 including a tapered hook portion 831, similar to hook portions 631, 731 of tine portions 630, 730, described above, wherein second width W2, in proximity to distal end 82 of hook segment 831, is less than first width W1, in proximity to a proximal end 81 of hook segment 831. FIGS. 11A-B further illustrate distal segment 832 having a width W3 that is greater than the second width W2. Distal segment 832, like distal segment 532 of component 53, includes tooth 520 and end 540 to facilitate tissue piercing without tearing, as described above. Like component 53, a thickness t of each tine portion 830, which is relatively constant along the entire length thereof, may be approximately 0.005 inch, and distal segment 832 thereof may conform to the aforementioned exemplary dimensions of tooth 520 and end 540.


In the foregoing detailed description, the invention has been described with reference to specific embodiments. However, it may be appreciated that various modifications and changes can be made without departing from the scope of the invention as set forth in the appended claims.

Claims
  • 1. A fixation component for an implantable medical device, the fixation component comprising: a base portion; anda plurality of tines that extend from the base portion, wherein each tine of the plurality of tines is elastically deformable between a pre-set position and an open position, and wherein each tine of the plurality of tines comprises a hook segment that, when positioned in the pre-set position, extends along a pre-set curvature, wherein the pre-set curvature is defined by at least a first radius and a second radius distal to the first radius, wherein the first radius is different than the second radius, and wherein the first radius and the second radius are nonzero.
  • 2. The fixation component of claim 1, wherein each tine of the plurality of tines further comprises a straight distal segment terminated by a tip, the straight distal segment distal of the hook segment.
  • 3. The fixation component of claim 1, wherein the first radius and the second radius extend in the same direction.
  • 4. The fixation component of claim 1, wherein the first radius is less than the second radius.
  • 5. The fixation component of claim 1, wherein the first radius is within a range from about 0.25 millimeters (mm) to about 1.04 mm, and wherein the second radius is within a range from about 1.65 mm to about 2.4 mm.
  • 6. The fixation component of claim 1, wherein the hook segment comprises at least one straight section extending between the first radius and the second radius.
  • 7. The fixation component of claim 6, wherein the at least one straight section is configured to flatten a profile of the open position of the at least one tine.
  • 8. The fixation component of claim 1, wherein the hook segment comprises a taper.
  • 9. The fixation component of claim 1, wherein the pre-set curvature is configured to reduce a tissue volume that is compressed by the at least one tine in the pre-set position.
  • 10. An implantable medical device (IMD) comprising: a hermetically sealed housing, the housing containing control electronics and a power source of the device and defining a longitudinal axis of the device; anda fixation component coupled to the hermetically sealed housing, the fixation component comprising: a base portion; anda plurality of tines that extend from the base portion, wherein each tine of the plurality of tines is elastically deformable between a pre-set position and an open position, and wherein each tine of the plurality of tines comprises a hook segment that, when positioned in the pre-set position, extends along a pre-set curvature, wherein the pre-set curvature is defined by at least a first radius and a second radius distal to the first radius, wherein the first radius is different than the second radius, and wherein the first radius and the second radius are nonzero.
  • 11. The IMD of claim 10, wherein the at least one tine further comprises a straight distal segment terminated by a tip, the straight distal segment distal of the hook segment.
  • 12. The fixation component of claim 11, wherein the straight distal segment is less than about 2.54 mm.
  • 13. The IMD of claim 10, wherein the first radius and the second radius extend in the same direction.
  • 14. The fixation component of claim 10, wherein the first radius is less than the second radius.
  • 15. The fixation component of claim 10, wherein the first radius is within a range from about 0.25 millimeters (mm) to about 1.04 mm, and wherein the second radius is within a range from about 1.65 mm to about 2.4 mm.
  • 16. The IMD of claim 10, wherein the hook segment comprises at least one straight section extending between the first radius and the second radius.
  • 17. The IMD of claim 16, wherein the at least one straight section is configured to flatten a profile of the open position of the at least one tine.
  • 18. The IMD of claim 10, wherein the pre-set curvature is configured to reduce a tissue volume that is compressed by the at least one tine in the pre-set position.
  • 19. A medical device system, comprising: an implantable medical device (IMD) comprising a hermetically sealed housing and a fixation component coupled to the hermetically sealed housing, the fixation component comprising: a base portion; anda plurality of tines that extend from the base portion, wherein each tine of the plurality of tines is elastically deformable between a pre-set position and an opened position, and wherein each tine of the plurality of tines comprises: a hook segment that, when positioned in the pre-set position, extends along a pre-set curvature, wherein the pre-set curvature is defined by a first radius and a second radius distal to the first radius, wherein the first radius is different than the second radius, and wherein the first radius and the second radius are nonzero; anda straight distal segment terminated by a tip, the straight distal segment distal of the hook segment; anda delivery catheter extending from a proximal end to a distal end having a distal opening defined by a wall configured to contain the IMB, wherein the straight distal segment, when positioned in the opened position inside the distal end, is oriented at an acute angle relative to the wall.
  • 20. The medical device system of claim 19, wherein the first radius is within a range from about 0.25 millimeters (mm) to about 1.04 mm, and wherein the second radius is within a range from about 1.65 mm to about 2.4 mm.
CROSS-REFERENCE TO RELATED APPLICATION

This application is a Continuation of U.S. patent application Ser. No. 13/955,393, filed Jul. 31, 2013, the content of which is incorporated herein by reference in its entirety.

US Referenced Citations (308)
Number Name Date Kind
721869 Dunning Mar 1903 A
3717151 Collett Feb 1973 A
3754555 Schmitt Aug 1973 A
3814104 Irnich et al. Jun 1974 A
3835864 Rasor et al. Sep 1974 A
3902501 Citron et al. Sep 1975 A
3943936 Rasor Mar 1976 A
3971364 Fletcher et al. Jul 1976 A
3976082 Schmitt Aug 1976 A
4103690 Harris Aug 1978 A
4112952 Thomas et al. Sep 1978 A
4269198 Stokes May 1981 A
4280512 Karr Jul 1981 A
4301815 Doring Nov 1981 A
4402328 Doring Sep 1983 A
4409994 Doring Oct 1983 A
4502492 Bornzin Mar 1985 A
4662382 Sluetz et al. May 1987 A
4898577 Badger et al. Feb 1990 A
4913164 Greene et al. Apr 1990 A
5003990 Osypka Apr 1991 A
5057114 Wittich et al. Oct 1991 A
5129749 Sato Jul 1992 A
5171233 Amplatz et al. Dec 1992 A
5193540 Schulman et al. Mar 1993 A
5257634 Kroll Nov 1993 A
5282845 Bush et al. Feb 1994 A
5300107 Stokes et al. Apr 1994 A
5318528 Heaven et al. Jun 1994 A
5336253 Gordon et al. Aug 1994 A
5405367 Schulman et al. Apr 1995 A
5405374 Stein Apr 1995 A
5411535 Fujii et al. May 1995 A
5425756 Heil et al. Jun 1995 A
5443492 Stokes et al. Aug 1995 A
5492119 Abrams Feb 1996 A
5522875 Gates et al. Jun 1996 A
5522876 Rusink Jun 1996 A
5545201 Helland et al. Aug 1996 A
5545206 Carson Aug 1996 A
5562723 Rugland et al. Oct 1996 A
5575814 Giele et al. Nov 1996 A
5578068 Laske et al. Nov 1996 A
5697936 Shipko et al. Dec 1997 A
5716390 Li Feb 1998 A
5716391 Grandjean Feb 1998 A
5755764 Schroeppel May 1998 A
5776178 Pohndorf et al. Jul 1998 A
5807399 Laske et al. Sep 1998 A
5837006 Ocel et al. Nov 1998 A
5837007 Altman et al. Nov 1998 A
5851226 Skubitz et al. Dec 1998 A
5871531 Struble Feb 1999 A
5908381 Aznoian et al. Jun 1999 A
5908447 Schroeppel et al. Jun 1999 A
6041258 Cigaina et al. Mar 2000 A
6055457 Bonner Apr 2000 A
6074401 Gardnier et al. Jun 2000 A
6078840 Stokes Jun 2000 A
6093177 Javier et al. Jul 2000 A
6129749 Bartig et al. Oct 2000 A
6132456 Sommer et al. Oct 2000 A
6181973 Ceron et al. Jan 2001 B1
6188932 Lindegren Feb 2001 B1
6240322 Peterfeso et al. May 2001 B1
6251104 Kesten et al. Jun 2001 B1
6290719 Garberoglio Sep 2001 B1
6321124 Cigaina Nov 2001 B1
6322548 Payne et al. Nov 2001 B1
RE37463 Altman Dec 2001 E
6358256 Reinhardt Mar 2002 B1
6363938 Saadat et al. Apr 2002 B2
6381495 Jenkins Apr 2002 B1
6381500 Fischer, Sr. Apr 2002 B1
6408214 Williams et al. Jun 2002 B1
6458145 Ravenscroft et al. Oct 2002 B1
6477423 Jenkins Nov 2002 B1
6500182 Foster Dec 2002 B2
6510332 Greenstein Jan 2003 B1
6510345 Van Bentem Jan 2003 B1
6522915 Ceballos et al. Feb 2003 B1
6572587 Lerman et al. Jun 2003 B2
6582441 He et al. Jun 2003 B1
6592581 Bowe Jul 2003 B2
6623518 Thompson et al. Sep 2003 B2
6626915 Leveillee Sep 2003 B2
6638268 Niazi Oct 2003 B2
6684109 Osypka Jan 2004 B1
6711443 Osypka Mar 2004 B2
6738672 Schulman et al. May 2004 B2
6743240 Smith et al. Jun 2004 B2
6755812 Peterson et al. Jun 2004 B2
6823217 Rutten et al. Nov 2004 B2
6909920 Lokhoff et al. Jun 2005 B2
6944507 Froberg Sep 2005 B2
6953454 Peterson et al. Oct 2005 B2
7027876 Casavant et al. Apr 2006 B2
7082335 Klein et al. Jul 2006 B2
7082336 Ransbury et al. Jul 2006 B2
7085606 Flach et al. Aug 2006 B2
7092765 Geske et al. Aug 2006 B2
7092766 Salys et al. Aug 2006 B1
7120504 Osypka Oct 2006 B2
7130700 Gardeski et al. Oct 2006 B2
7149587 Wardle et al. Dec 2006 B2
7158838 Seifert et al. Jan 2007 B2
7162310 Doan Jan 2007 B2
7181288 Rezai et al. Feb 2007 B1
7187982 Seifert et al. Mar 2007 B2
7200437 Nabutovsky et al. Apr 2007 B1
7212869 Wahlstrom et al. May 2007 B2
7229415 Schwartz Jun 2007 B2
7251532 Hess et al. Jul 2007 B2
7289853 Campbell et al. Oct 2007 B1
7313445 McVenes et al. Dec 2007 B2
7326231 Phillips et al. Feb 2008 B2
7328071 Stehr et al. Feb 2008 B1
7331922 Mohl Feb 2008 B2
7383091 Chitre et al. Jun 2008 B1
7450999 Karicherla et al. Nov 2008 B1
7462184 Worley et al. Dec 2008 B2
7463933 Wahlstrom et al. Dec 2008 B2
7499758 Cates et al. Mar 2009 B2
7509169 Eigler et al. Mar 2009 B2
7515971 Doan Apr 2009 B1
7532939 Sommer et al. May 2009 B2
7558631 Cowan et al. Jul 2009 B2
7634319 Schneider et al. Dec 2009 B2
7647109 Hastings et al. Jan 2010 B2
7657325 Williams Feb 2010 B2
7678128 Boyle et al. Mar 2010 B2
7717899 Bowe et al. May 2010 B2
7731655 Smith et al. Jun 2010 B2
7734343 Ransbury et al. Jun 2010 B2
7740640 Ginn Jun 2010 B2
7785264 Hettrick et al. Aug 2010 B2
7799037 He et al. Sep 2010 B1
7801624 Flannery et al. Sep 2010 B1
7835801 Sundararajan et al. Nov 2010 B1
7840281 Kveen et al. Nov 2010 B2
7840283 Bush et al. Nov 2010 B1
7860580 Falk et al. Dec 2010 B2
7875049 Eversull et al. Jan 2011 B2
7890186 Wardle et al. Feb 2011 B2
7904179 Rutten et al. Mar 2011 B2
7920928 Yang et al. Apr 2011 B1
7949395 Kuzma May 2011 B2
7993351 Worley et al. Aug 2011 B2
8010209 Jacobson Aug 2011 B2
8012127 Lieberman et al. Sep 2011 B2
8032219 Neumann et al. Oct 2011 B2
8036757 Worley Oct 2011 B2
8057486 Hansen Nov 2011 B2
8082035 Glukhovsky Dec 2011 B2
8103361 Moser Jan 2012 B2
8108054 Helland Jan 2012 B2
8142347 Griego et al. Mar 2012 B2
8160722 Rutten et al. Apr 2012 B2
8170690 Morgan et al. May 2012 B2
8185213 Kveen et al. May 2012 B2
8219213 Sommer et al. Jul 2012 B2
8233994 Sommer et al. Jul 2012 B2
8252019 Fleming, III Aug 2012 B2
8262672 Neidert et al. Sep 2012 B2
8295939 Jacobson Oct 2012 B2
8313445 Mishima et al. Nov 2012 B2
8352025 Jacobson Jan 2013 B2
8352028 Wenger Jan 2013 B2
8364277 Glukhovsky Jan 2013 B2
8364280 Marnfeldt et al. Jan 2013 B2
8406900 Barlov et al. Mar 2013 B2
8406901 Starkebaum et al. Mar 2013 B2
8418362 Zerfas Apr 2013 B2
8428750 Kolberg Apr 2013 B2
8452420 Flach et al. May 2013 B2
8478431 Griswold et al. Jul 2013 B2
8489189 Tronnes Jul 2013 B2
8494650 Glukhovsky et al. Jul 2013 B2
8504156 Bonner et al. Aug 2013 B2
8518060 Jelich et al. Aug 2013 B2
8527068 Ostroff Sep 2013 B2
8532790 Griswold Sep 2013 B2
8548605 Ollivier Oct 2013 B2
8565897 Regnier et al. Oct 2013 B2
8615310 Khairkhahan et al. Dec 2013 B2
8634912 Bornzin et al. Jan 2014 B2
8670842 Bornzin et al. Mar 2014 B1
8700181 Bornzin et al. Apr 2014 B2
8721587 Berthiaume et al. May 2014 B2
8727996 Allan et al. May 2014 B2
8738147 Hastings et al. May 2014 B2
8755909 Sommer et al. Jun 2014 B2
8758365 Bonner et al. Jun 2014 B2
9119959 Rys et al. Sep 2015 B2
9155882 Grubac et al. Oct 2015 B2
9283381 Grubac Mar 2016 B2
9414857 Wood et al. Aug 2016 B2
9446248 Sheldon et al. Sep 2016 B2
9526891 Eggen et al. Dec 2016 B2
9539423 Bonner et al. Jan 2017 B2
10071243 Kuhn et al. Sep 2018 B2
10099050 Chen et al. Oct 2018 B2
20020077556 Schwartz Jun 2002 A1
20020095203 Thompson et al. Jul 2002 A1
20030004537 Boyle et al. Jan 2003 A1
20030233139 Chitre et al. Dec 2003 A1
20040034401 Dahlberg Feb 2004 A1
20040147973 Hauser Jul 2004 A1
20040176797 Opolski Sep 2004 A1
20040230280 Cates Nov 2004 A1
20040249417 Ransbury et al. Dec 2004 A1
20050090890 Wu et al. Apr 2005 A1
20050267555 Marnfeldt et al. Dec 2005 A1
20060085039 Hastings et al. Apr 2006 A1
20060247753 Wenger et al. Nov 2006 A1
20070043414 Fifer et al. Feb 2007 A1
20070135883 Drasler et al. Jun 2007 A1
20070150037 Hastings et al. Jun 2007 A1
20070150038 Hastings et al. Jun 2007 A1
20070233218 Kolberg Oct 2007 A1
20070239248 Hastings et al. Oct 2007 A1
20070255376 Michels et al. Nov 2007 A1
20070276444 Gelbart Nov 2007 A1
20070293904 Gelbart Dec 2007 A1
20080021532 Kveen et al. Jan 2008 A1
20080051863 Schneider Feb 2008 A1
20090082827 Kveen et al. Mar 2009 A1
20090082828 Ostroff Mar 2009 A1
20090204170 Hastings et al. Aug 2009 A1
20090281605 Marnfeldt et al. Nov 2009 A1
20100131036 Geistert et al. May 2010 A1
20100198288 Ostroff Aug 2010 A1
20100211149 Morgan et al. Aug 2010 A1
20110034939 Kveen et al. Feb 2011 A1
20110054555 Williams et al. Mar 2011 A1
20110112548 Fifer et al. May 2011 A1
20110125163 Rutten et al. May 2011 A1
20110190785 Gerber et al. Aug 2011 A1
20110190786 Gerber et al. Aug 2011 A1
20110208260 Jacobson Aug 2011 A1
20110237967 Moore et al. Sep 2011 A1
20110251660 Griswold Oct 2011 A1
20110251661 Fifer et al. Oct 2011 A1
20110251662 Griswold et al. Oct 2011 A1
20110270339 Murray, III et al. Nov 2011 A1
20110270340 Pellegrini et al. Nov 2011 A1
20110282423 Jacobson Nov 2011 A1
20110307043 Ollivier Dec 2011 A1
20120078322 Dal Molin et al. Mar 2012 A1
20120078336 Helland Mar 2012 A1
20120095539 Khairkhahan et al. Apr 2012 A1
20120108986 Beasley May 2012 A1
20120109002 Mothilal et al. May 2012 A1
20120109079 Asleson et al. May 2012 A1
20120109148 Bonner et al. May 2012 A1
20120109149 Bonner et al. May 2012 A1
20120116489 Khairkhahan et al. May 2012 A1
20120158111 Khairkhahan et al. Jun 2012 A1
20120165827 Khairkhahan et al. Jun 2012 A1
20120172690 Anderson et al. Jul 2012 A1
20120172891 Lee Jul 2012 A1
20120172892 Grubac et al. Jul 2012 A1
20120197373 Khairkhahan et al. Aug 2012 A1
20120232565 Kveen et al. Sep 2012 A1
20120271134 Allan et al. Oct 2012 A1
20120330392 Regnier et al. Dec 2012 A1
20130006261 Lampropoulos et al. Jan 2013 A1
20130006262 Lampropoulos et al. Jan 2013 A1
20130012925 Berthiaume et al. Jan 2013 A1
20130035636 Beasley et al. Feb 2013 A1
20130035748 Bonner et al. Feb 2013 A1
20130053921 Bonner et al. Feb 2013 A1
20130079798 Tran et al. Mar 2013 A1
20130079861 Reinert et al. Mar 2013 A1
20130103047 Steingisser et al. Apr 2013 A1
20130103049 Bonde Apr 2013 A1
20130110127 Bornzin et al. May 2013 A1
20130110219 Bornzin et al. May 2013 A1
20130116738 Samade et al. May 2013 A1
20130116740 Bornzin et al. May 2013 A1
20130116741 Bornzin et al. May 2013 A1
20130123875 Varady et al. May 2013 A1
20130131591 Berthiaume et al. May 2013 A1
20130131693 Berthiaume et al. May 2013 A1
20130233345 Baarsch et al. Sep 2013 A1
20130253342 Griswold et al. Sep 2013 A1
20130253343 Waldhauser et al. Sep 2013 A1
20130253344 Griswold et al. Sep 2013 A1
20130253345 Griswold et al. Sep 2013 A1
20130253346 Griswold et al. Sep 2013 A1
20130253347 Griswold et al. Sep 2013 A1
20130296957 Tronnes Nov 2013 A1
20140058494 Ostroff et al. Feb 2014 A1
20140074114 Khairkhahan et al. Mar 2014 A1
20140107723 Hou et al. Apr 2014 A1
20140148815 Wenzel et al. May 2014 A1
20140180306 Grubac et al. Jun 2014 A1
20150039069 Rys et al. Feb 2015 A1
20150039070 Kuhn et al. Feb 2015 A1
20150039071 Grubac et al. Feb 2015 A1
20150051616 Hassl et al. Feb 2015 A1
20150051682 Schmidt et al. Feb 2015 A1
20150094668 Wood et al. Apr 2015 A1
20150352353 Rys et al. Dec 2015 A1
20160001068 Grubac et al. Jan 2016 A1
20160059002 Grubac et al. Mar 2016 A1
20160094668 Chang et al. Mar 2016 A1
20170209688 Drake et al. Jul 2017 A1
Foreign Referenced Citations (20)
Number Date Country
1003904 Jan 1977 CA
1882370 Dec 2006 CN
1882370 Dec 2006 CN
2053919 May 1972 DE
0212955 Mar 1987 EP
779080 May 2003 EP
H02-88666 Jul 1990 JP
05245215 Sep 1993 JP
2011151104 Jun 2013 RU
WO9520993 Aug 1995 WO
WO0102053 Jan 2001 WO
03032807 Apr 2003 WO
2004028348 Apr 2004 WO
2009039400 Mar 2009 WO
2009042295 Apr 2009 WO
2010131157 Nov 2010 WO
2012092067 Jul 2012 WO
2012092074 Jul 2012 WO
WO12135530 Oct 2012 WO
2014006471 Jan 2014 WO
Non-Patent Literature Citations (17)
Entry
Chinese Office Action dated Sep. 6, 2016, Application No. 201480038011.7, English transaltion, 4 pages.
(PCT/US2014/047962)PCT Notification of Transmittal of the International Search Report and the Written Opinion of the International Searching Authority, dated Oct. 10, 2014, 11 pages.
International Search Report from Written Opinion from International Application No. PCT/US2014/047962, dated Feb. 5, 2015, 6 pp.
International Preliminary Report on Patentability from International Application No. PCT/US2014/047962, dated Feb. 2, 2016, 11 pp.
Chinese Office Action dated Sep. 6, 2016, Application No. 201480038011.7 Chinese translation, 9 pages.
Chinese Office Action dated Sep. 6, 2016, Application No. 201480038011.7 English translation, 4 pages.
U.S. Appl. No. 16/158,724, filed by Xin Chen et al., filed Oct. 12, 2018.
Prosecution History from U.S. Appl. No. 13/955,393, dated from Nov. 26, 2014 through Aug. 10, 2018, 104 pp.
Notice of Allowance from U.S. Appl. No. 15/410,161, dated Jun. 13, 2018, 5 pp.
“Homer Mammalok Gold,” accessed on or about Jan. 19, 2017, accessed from http://www.mana-tech.com/factsheets/HomerMammalok.pdf, 1 pp.
Medtronic model Selectrsuretm™ 3830 manual, 2013, accessed on or about Jan. 19, 2017, 20 pp.
Merriam-Webster Definition of “Compound Curve,” accessed on Apr. 25, 2017, https://merriam-webster.com/dictionary/compound%20curve, 4 pp.
Spickler, et al., “Totally Self-Contained Intracardiac Pacemaker,” J. Electrocardiology, vol. 3, Nos. 3 & 4, pp. 325-331, 1970. (Applicant points out, in accordance with MPEP 609.04(a), that the year of publication, 1970 is sufficiently earlier than the effective U.S. filing date, so that the particular month of publication is not in issue.).
Prosecution History from U.S. Appl. No. 15/410,085, dated from Nov. 2, 2018 through Feb. 7, 2019, 17 pp.
Notice of Allowance from U.S. Appl. No. 15/410,085, dated Jun. 26, 2019, 8 pp.
Prosecution History from U.S. Appl. No. 16/158,724, dated from Oct. 12, 2018 to Nov. 29, 2018, 38 pp.
Response to Office Action dated Feb. 7, 2019, from U.S. Appl. No. 15/410,085, filed May 6, 2019, 13 pp.
Related Publications (1)
Number Date Country
20190009078 A1 Jan 2019 US
Continuations (1)
Number Date Country
Parent 13955393 Jul 2013 US
Child 16128270 US